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ABSTRACT 
 
Elucidating the mechanism of over and under expression of proteins is critical in developing a better understanding of cancer. Multiple 
techniques are used to examine differential expression of proteins in cells and assess changes in protein expression in response to 
therapies such as radiation. Reduced expression can be caused by protein inactivation, mRNA instability, or reduced transcription. The 
following protocol was used to determine the mechanism for the reduced expression of an antiapoptotic factor, survivin, in normal 
tissues in response to radiation and the defect in cancer cells that prevents this reduction. We also examined ways to overcome survivin 
over expression in cancer cells in order to sensitize them to radiation. We will focus on the use of antisense oligonucleotides, cell cycle 
analysis, and luciferase reporter genes. 
 
 
INTRODUCTION 
 
Regulators of cell death are commonly mutated in numerous 
cancers. Survivin, a member of the inhibitors of apoptosis family 
(IAP), is known to decrease apoptosis when it is over expressed 
in cells (1). Survivin is known to be over expressed in many 
cancer cell lines (2) and is associated with decreased survival, 
increased radiation resistance, and increased recurrence (3). 
Hence, we were interested in survivin as a therapeutic target for 
radiosensitization of H460 lung cancer cells. Survivin provides an 
attractive target for cancer therapy because it is not expressed in 
most terminally differentiated tissue but highly expressed in 
several cancers (3, 4). In recent studies it has been found that not 
only is it important to determine the presence of a protein in 
tumors, but also the extent to which it has been over or under 
expressed (5). We therefore sought to determine survivin levels 
and found that survivin decreased in Human Umbilical Vein Shinohara et al.    
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Endothelial Cells (HUVEC) in response to radiation but there 
was no such decrease in survivin in several cancer cell lines 
treated with radiation. Results showed that decreased survivin in 
HUVEC was caused by a non-p53 dependent suppression of 
survivin mRNA transcription. Increased survivin caused 
radioresistance, but this resistance could be attenuated with 
inhibition of survivin. 
 
To determine the mechanism of action for this radioresistance in 
tumor cells we employ several methods, but we will focus on the 
use of luciferase reporter genes, flow cytometry quantification of 
cell cycle phases and antisense oligonucleotide (ASO) inhibition 
of survivin. Antisense Oligonucleotides (ASO) are a valuable 
research tool. ASO has been used to inhibit several kinases (1, 6, 
7), defective gene products (8), and specific receptors (9). ASO 
has also shown potential for use as a therapeutic in 
antiangiogenesis and as a radiosensitizer in cancer (1). ASO are a 
useful inhibitor of mRNA translation, resulting in the attenuation 
of the related protein product. There are several ways this can 
occur, such as inhibition of ribosomal binding, and activation of 
RNase H. Since ASO are designed to hybridize to specific 
mRNA sequences, the specificity can be high. Furthermore, 
rather than just inhibiting a protein the ASO prevents protein 
formation. After transfection, protein expression can be 
conveniently quantified using western blot. 
 
MATERIALS AND METHODS 
 
Cell culture, adenoviral vectors, and chemicals 
 
HUVECs were obtained from Clonetics and were maintained in 
endothelial basal medium-2 (EBM-2) medium supplemented with 
endothelial growth medium (EGM-2) MV single aliquots 
(BioWhittaker). Various cancer cell lines were obtained from 
American Type Culture Collection and cultured in their required 
media. Val138 cell (a gift from Dr. Maureen Murphy, Fox Chase 
Cancer Center, Philadelphia, PA) originates from human lung 
adenocarcinoma cell line H1299 stably transfected with 
temperature-sensitive p53 mutant. Val138 cells were cultured in 
DMEM (DMEM, Invitrogen) plus 10% fetal bovine serum, 100 
units/ml penicillin and streptomycin, and 0.8 mg/ml Geneticin. 
HEK 293 cells (American Type Culture Collection) transfected 
with pCDNAhis-survivin or pCDNAhis vector were selected in 
DMEM with 10% FCS and 0.5 mg/ml G418 (Invitrogen). Single 
cell clones overexpressing survivin or neomycin control were 
confirmed by immunoblotting. Actinomycin D (Sigma) was used 
at a final concentration of 5 µg/ml. Irradiation (3 Gy) was given 
1 h after the drug was added, by use of a Colbalt-60 radioactive 
source. Adenoviral vectors overexpressing LacZ and p53 were 
gifts from Dr. Shuang Huang, The Scripps Research Institute 
(San Diego, CA). 
 
Western immunoblots 
 
Cells were treated with 3 Gy and various drugs and collected at 
various time points. The cells were counted and then were 
washed with ice-cold PBS twice before the addition of lysis 
buffer (20 nM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl 
fluoride, and leupeptin). Protein concentration was quantified by 
the Bio-Rad method. Equal amounts of protein were loaded into 
each well and separated by 14% SDS-PAGE gel, followed by 
transfer onto nitrocellulose membranes. Membranes were 
blocked by use of 10% nonfat dry milk in PBS for 2 h at room 
temperature. The blots were then incubated with the rabbit-
antihuman [survivin (R&D systems), p53 and phospho-p53-
serine 15 (Cell Signal), cleaved caspase 3 (Cell Signal)] antibodies 
overnight at 4°C. Donkey antirabbit IgG secondary antibody 
(1:1000; Amersham) was incubated for 1 h at room temperature. 
Immunoblots were developed by using the enhanced 
chemiluminescence (ECL) detection system (Amersham) 
according to the manufacturer’s protocol and autoradiography. 
 
Flow cytometry 
 
Cells were trypsinized, rinsed once, resuspended in PBS, and 
fixed with ice-cold 70% ethanol for at least 20 min. Fixed cells 
were then rinsed again with PBS and resuspended in 50 µg/ml 
propidium iodide (Sigma) with 40 kilounits (KU)/ml of DNase-
free RNase (Stratagene, La Jolla, CA). Cells were then run on a 
Becton Dickinson FACScan flow cytometer, and the percentage 
of cells in each phase was calculated using ModFit software. 
 
Real-time quantitative reverse transcription-PCR 
 
Total RNA was isolated from cell culture, using a Qiagen RNA 
extraction kit. After RNA isolation, cDNA was prepared from 
each sample as described previously (10). Quantification of 
cDNA and an internal reference gene (β-actin) was conducted 
using a fluorescence-based real-time detection method [ABI 
PRISM 7700 Sequence Detection system (TaqMan); Perkin-
Elmer Applied Biosystems, Foster City, CA], as described 
previously (11, 12). All of the quantitative reverse transcription-
PCR experiments were performed as triplicates. The PCR 
mixture consisted of 600 nmol/liter of each primer, 200 
nmol/liter probe (sequences used are given below), 5 units of 
AmpliTaq Gold polymerase, 200 µM each dATP, dCTP, and 
dGTP, 400 µM dUTP, 5.5 mM MgCl2, and 1X TaqMan buffer A 
containing a reference dye, to a final volume of 25 µl (all of the 
reagents were supplied by Perkin-Elmer Applied Biosystems). 
Cycling conditions were 50°C for 10 s and 95°C for 10 min, 
followed by 46 cycles at 95°C for 15 s and 60°C for 1 min. 
Colon, liver, and lung RNAs (all from Stratagene, La Jolla, CA) 
were used as control calibrators on each plate. Primer and probe 
sequences of the analyzed genes are as follows: 
  
Survivin 
 
Forward primer: 5'-TGC CCC GAC GTT GCC-3’ 
Reverse primer: 5’-CAG TTC TTG AAT GTA GAG ATG 
CGG T-3’ 
Probe: 6FAM-5’-CCT GGC AGC CCT TTC TCA AGG ACC-
3’-TAMRA Shinohara et al.    
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β-actin 
 
Forward primer: 5’-TGAGCGCGGCTACAGCTT-3’ 
Reverse primer: 5’-TCCTTAATGTCACGCACGATTT-3’ 
Probe: 6FAM-5’-ACCACCACGGCCGAGCGG-3’-TAMRA 
 
COX-2 
 
Forward primer: 5’-GCTCAAACATGATGTTTGCATTC-3’ 
Reverse primer: 5’-GCTGGCCCTCGCTTATGA-3’ 
Probe: 6FAM-5’-TGCCCAGCACTTCACGCATCAGTT-3’-
TAMRA 
 
Plasmid, AS oligonucleotides, transfection and 
luciferase assays 
 
Sp1 plasmid (a gift of Dr. M. Murphy from Fox Chase Cancer 
Center) contains 1.1 kb of the survivin promoter in a Luciferase 
reporter construct, pCR2.1 vector (Invitrogen). The expression 
plasmid of mutant p53 was a gift of Dr. Jennifer Pietenpol, 
Vanderbilt University, Nashville, TN). Sp1 plasmid (2.5 µg) or 
2.5 µg of SP1 plus 2.5 µg of p53 mutant plasmid was transiently 
transfected into 60–70% confluent HUVECs grown in 3.5-cm 
plates, by a F1 Targetfect (Targeting systems). After 24 h, cells 
were irradiated with 3 Gy. They were collected at 0, 4, 8, and 16 h 
after irradiation. Cells were lysed and luciferase assays were 
performed as the protocol from the manufacturer (Promega) on 
a Monolight 3010 Luminometer (PharMingen). Luciferase 
activity was normalized to total protein levels. The entire 
experiment was carried out in triplets. The luciferase activity was 
measured from 1.6 µg of protein lysates. Antisense (AS) 
oligonucleotides were synthesized (Qiagen, Inc) using the 
following sequences: the survivin AS oligonucleotides: 5’-
TGTGC-TATTCTGTGAATT-3’; the mismatch control 
oligonucleotide: 5’-TAAGC-TGTTCTATGTGTT-3’. The 
underlined nucleotides are 2’-O-methoxyethyl modified. 
Subconfluent H460 cells were transfected with either of the 
oligonucleotides, using Lipofectin with a mixture of Lipofectin 
(Life Technologies, Inc., Baltimore, MD) and oligonucleotides in 
Opti-MEM medium (Life Technologies, Inc.) at a ratio of 3 µl 
Lipofectin/ml medium per 100 nM oligonucleotide. After 4 h of 
incubation, cells were replaced by the regular complete medium. 
 
3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) assay 
 
Briefly, various types of cells were seeded at a density of 2000-
5000 cells/well in 96-well plates, were grown overnight, and were 
exposed to 3 Gy alone or were transfected by AS 
oligonucleotides before irradiation. After 48 or 72 h of 
incubation, 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) was added (50 µg/well) for 4 h. Solubilization of 
the converted purple formazan dye was accomplished by placing 
cells in 100 µl of 0.01 N HCl/10% SDS and incubating overnight 
at 37°C. The reaction product was quantified by absorbance at 
570 nm. All of the samples were assayed in triplicate, and data 
were analyzed by Student’s t test. 
RESULTS AND DISCUSSION 
 
Survivin expression in HUVEC versus cancer tissue 
 
Initially we found that human cells, such as HUVEC, showed a 
decrease in suvivin levels in response to radiation, however 
survivin levels did not decrease in cancer cells treated with 
radiation as shown by western blot analysis. Reduction of 
survivin levels in normal HUVEC was found to be due to 
transcriptional suppression. This was determined by isolating the 
total cellular RNA from HUVEC treated with 3 Gy of radiation. 
Real time PCR was then used to quantify survivin mRNA as 
shown in Figure 1. 
 
Fig. 1: HUVEC levels of survivin after 3 Gy. HUVEC were irradiated with 3 
Gy and RNA was collected at the indicated time points. RNA was then quantified 
using Taqman real time PCR. 
 
β-actin mRNA was used as an internal control. However, when 
colorectal cancer cell lines were tested in a similar fashion, there 
was no reduction in the transcription of survivin. To determine 
what caused the reduced transcription of survivin mRNA in 
HUVEC cells we first examined mitosis rates to see whether the 
reduced survivin level was secondary to a reduction in the 
number of mitotic cells. To do this cell-cycle distribution was 
examined via flow cytometry at various time points in HUVEC 
after radiation. Results showed no significant variation in the 
number of cells in G2-M phase post irradiation. Flow cytometry 
was selected due to rapid quantification of cells in each stage and 
its effectiveness in previous studies (13) as shown in Figure 2.  
 
Fig. 2: Percentage of HUVEC cells in G-M phase at various time points 
after radiation. Shown are the averages with the standard deviation based on the 
results of 3 experiments. Shinohara et al.    
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Determining the mechanism of decreased survivin 
expression 
 
We next examined whether reduced survivin was due to reduced 
stability of the mRNA secondary to radiation. We treated 
HUVEC with actinomycin D alone or actinomycin D with 3 Gy 
given 1 hour later. Neither treatment group showed decreased 
stability of survivin mRNA. Cox-2 mRNA was used as a control 
and showed a two-thirds reduction 2 hours after either treatment. 
These findings suggested that the reduction in survivin 
expression was not due to degradation of mRNA and likely due 
to a reduction in transcription. To test this we transfected 
HUVEC with a luciferase reporter under the control of a 1.1 kb 
survivin promoter fragment. Hence, transfected cells would only 
express luciferase if survivin transcription was present after 
irradiation. Transfected HUVEC showed a significantly reduced 
luciferase activity after radiation.  
 
Lipofectin and F1 were selected as transfection agents in our 
experiment due to our previous experience using them. When 
starting to use a new transfection agent the toxicity and 
transfection efficiency must be balanced for each cell type. 
T o x i c i t y  i s  a s s o c i a t e d  w i t h  h i g h  l e v e l s  o f  D N A / R N A  t o  b e  
transfected, large amounts of transfection agent used, and long 
duration of transfection. Unfortunately, these factors also 
increase transfection efficiency; hence pilot experiments are 
needed to balance these two effects. Increasing the number of 
cells plated may also help with transfection efficiency. We have 
found that HUVEC and human cell lines in general are more 
difficult to transfect at an acceptable level without toxicity. 
Through pilot experiments we found that lipofectin has adequate 
results in cancer cells but that F1 reagent (Targeting Systems) was 
most effective for use in HUVEC. We have also found that 
greatest transfection rates are achieved with the use of Opti-
MEM media (Life Technologies Inc.), a serum free media with 
the minimal requirements for cell survival. 
 
Determining p53’s role in survivin expression 
 
P53 is known to be activated in response to irradiation (14). P53 
has also been shown to have activity on survivin levels in 
response to DNA damage (15). We wanted to examine whether 
reduced survivin levels in HUVEC occurred in a p53 dependent 
fashion. P53 levels were examined in irradiated HUVEC via 
western blot and showed that p53 phosphorylation increased in 
response to radiation. Total p53 did not change in response to 
radiation. Survivin level response to increased p53 was tested 
using an adenovirus to overexpress wild type p53. In HUVEC 
overexpressing p53 there was a decrease in survivin levels.  
 
To determine how p53 over expression effects survivin levels in 
cancer cells, we used a lung cancer cell line, Val138, which has 
temperature dependent p53 mutant activity. Survivin levels were 
higher when defective mutant p53 was expressed at 39ºC, and 
radiation did not reduce these levels. Furthermore, even when 
normal p53 was expressed at 32ºC there was no decrease in 
survivin in response to radiation. To confirm this we 
cotransfected an expression plasmid mutant of p53 with a 
luciferase reporter activated by the 1.1 kb survivin promoter 
fragment into HUVEC cells. Survivin promoter was shown to 
have an increased expression in general with mutant p53 as 
shown in Figure 3. However, though the survivin promoter had 
greater activity in p53 mutants this did not prevent radiation 
induced attenuation of survivin promoter expression. 
 
Fig. 3: Survivin mRNA levels relative to β-actin levels in Val38. Shown are 
the relative levels of survivin in reference to β-actin in irradiated Val38 cells at 
either 32 or 39 degrees. 
 
Survivin’s role in radiosensitization 
 
To determine if survivin over expression affects 
radiosensitization, cells with normal levels of survivin and cells 
overexpressing survivin were treated with radiation. Western blot 
probing for cleaved caspase 3 showed that cells with increased 
survivin levels had markedly less apoptosis in response to 
radiation compared with cells which expressed normal levels of 
survivin.  
  
To determine whether inhibition of survivin over expression 
could induce a radiosensitive phenotype in cancer cells, an ASO 
for survivin was used. To control for transfection toxicity, a 
missense control oligo was used. Again, optimal amounts of 
DNA, and transfection agent must be determined to minimize 
toxicity while maintaining adequate levels of transfection for each 
cell line used. Reduced survivin levels were confirmed with 
western blot. H460 cells treated with survivin ASO alone or 3 Gy 
alone showed a 20% decrease in viability but when 3 Gy was 
given concomitantly with survivin ASO there was a 2-3 fold 
decrease in cell viability as shown in Figure 4. 
 
Fig. 4: MTT assay of H460 cells treated with Anti-survivin ASO. H460 cells 
were treated with either missense (MS) or anti-survivin ASO and then given 0 or 
3 Gy. Shown are the means and standard deviations based on three separate 
experiments. Shinohara et al.    
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Discussion of antisense oligonucleotides 
 
We have used ASO in several experiments to inhibit the 
expression of proteins (1). An ASO for survivin was chosen 
because an effective sequence had already been developed. This 
was done due to the variability in effectiveness of ASO. This 
occurs because the ASO must interact with an accessible segment 
of mRNA and because mRNA structure is affected by internal 
base composition and a number of proteins, this makes it 
difficult to predict in vivo mRNA structure (16). Hence, we 
chose a sequence that has been well established previously. 
Secondly, it can be difficult to get ASO to their target sequence. 
We used Lipofectin as a transfection agent to overcome 
problems with poor uptake of ASO into cells and rapid 
intracellular degradation. 
 
There is great potential for the use of ASO in therapeutics. There 
have been several studies that have shown that ASO used in 
research may be useful as therapeutic agents in humans (17) and 
the FDA has already approved an ASO for therapeutic use (18). 
ASO are short oligonucleotides (13-25 nucleotides) which are 
thought to hybridize to a specific mRNA sequence. 
Pharmacologic inhibitors for survivin have been developed such 
as the cyclin-dependent kinase inhibitor flavopiridol which 
inhibits survivin phosphorylation (3). A dominant negative (DN) 
for survivin can also be used to inhibit its activity (19). ASO was 
chosen over a pharmacological agent because of the lack of 
availability for a specific inhibitor of survivin. Compounds such 
as flavopiridol inhibit survivin activity, but also have effects on 
numerous other proteins. ASO and DN are often both 
performed to confirm results of a given study. We choose ASO 
due to its effectiveness is previous studies. 
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PROTOCOLS 
 
Flow cytometry 
 
Day 1: 
 
a.  Plate approximately 4 x 105 HUVEC cells into 25-cm2 flasks.  
b.  Incubate cells at 37ºC overnight. 
 
Day2:  
 
a.  Treat HUVEC with 3 Gy and collect cells at desired time points (0, 4 and 24 hours in this experiment). 
b.  Collect cells for analysis by washing cells with PBS 2 times and trypsinize with 0.5 ml of trypsin per flask.  
c.  After 5 minutes add 3 ml of PBS to cells and pipette mix into 5 ml Falcon tubes. 
d.  Spin cells for 5 min at 2000 rpm. Gently suction out supernatant. This step removes trypsin. 
e.  Resuspend cells in 5 ml of ice cold Ethanol (70%) for 20 minutes to fix cells.  
f.  Centrifuged cells at 2000 rpm for 5 minutes and carefully suction out supernatant. 
g.  Resuspend cells in PBS containing 50 µg/ml of propridium iodide (Sigma) with 40 kilounits (KU/ml) of DNase-free RNase 
(Strategene, La Jolle, CA). 
h.  Run cells on a Becton Dickinson FACScan flowcytometer and use ModFit software to calculate the percentage of cells in each 
phase of the cell cycle. 
i.  *Note: Do not process large number of fixed cells (more than 106) as one may get incomplete staining of cells. 
   
Transfection of cells with luciferase reporter 
 
1.  To optimize transfections ideal concentrations of transfection agent and DNA must be determined. 
a.  One day prior to transfection, plate HUVEC cells (approximately 2 X 105 cells) onto 3.5 cm plates. Ideal confluence is 50-70% 
on the day of transfection. 
b.  Pipette 660 µl of Opti-MEM media (Life Technologies Inc.) into 8 eppendorf tubes labeled 1-8. 
c.  *Note: Do not add antibacterials or serum to transfection media. 
d.  Pipette 2.5 µg of Luciferase plasmid into tubes 1-4 and pipette 5 µg of plasmid into tubes 5-8. Flick tubes gently 15 times to 
vortex. 
e.  Using vortex, mix F-1 reagent (Targeting Systems) at full speed for 20 seconds.  
f.  Pipette 2.5, 5.0,10, and 15 µl of F-1 reagent into tubes 1-4 and 5-8. 
g.  Incubate tubes at 37°C for 20 minutes to allow the formation of transfection complexes. 
h.  Plated cells were washed with 2.0 ml opti-MEM and then 2.0 ml of opti-MEM media was added. The entire eppendorf of 
transfection complex is then added to each plate.  
i.  Incubate cells for two hours and then remove opti-MEM media. Wash cells gently with opti-MEM media and replaced with 
HUVEC media. 
j.  Incubate cells overnight at 37°C and then treat with 3 Gy of radiation. 
k.  Lyse cells with 200 µl of lysis buffer  (20 nM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, and leupeptin). Perform Luciferase assay according to Promega protocol 
on a Monolight 3010 Luminometer (Pharmingen). 
l.  Set up the same experiment with the two best F-1 concentration and vary DNA concentrations from 1, 2, 4, 8 µg to optimize 
DNA concentrations. Further optimization may be necessary using different concentrations. Time of transfection and number 
of cells plated may also need to be optimized. 
m.  Increased incubation time will generally increase transfection but toxicity as well. To attenuate toxicity serum may need to be 
added during transfections particularly transfections longer than 12 hours. However, serum may affect amount of transfection 
agent needed. 
n.  Note: β-galactosidase or GFP are effective ways to test for efficacy of transfection without a luminometer. 
2.  Ideal protein concentration was found to be 5 µg DNA and 15 µl of F-1 reagent for HUVEC cell transfection. 
a.  Adjust amounts of DNA and reagent to optimize transfection rates with minimal toxicity based on preliminary study. 
b.  Peak levels of transfection achieved in HUVEC was 30% using the F-1 reagent. If greater transfection rates are needed, 
Enhancer (Targeting Systems) can be used during the formation of transfection agent step. 
c.  For experimental transfection follow above protocol replacing your ideal DNA and F-1 concentrations accordingly. 
 Shinohara et al.    
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Transfection of ASO with lipofectin 
 
Note optimization of transfection will need to be performed as in the protocol for luciferase transfection. 
 
Day 1:  
 
a.  Trypsinize H460 cells and replated onto 96 well plates (approximately 2000-5000 cells per well) with the goal of 50-70% confluence 
on day 2 of transfection protocol. 
 
Day 2: 
 
a.  After optimization, it was found that 100nM of oligonucleotide and 3 µl of Lipofectin/ml was ideal for transfection of H460 cells. 
There is a transfection enhancer available for lipofectin (Invitrogen) if higher transfection rates are desired.  
b.  Create a stock solution sufficient for all samples. Two separate solutions need to be made, a plasmid solution and a Lipofectin 
solution of equal volumes. They will be combined to form the final total volume of transfection complex. Each well holds 100 µl 
of solution so for 30 wells, 3 ml of transfection complex would be needed and hence, 1.5 ml of plasmid and lipofectin solutions. 
c.  *Note: Opti-MEM media was used for transfection, transfection media should not contain antibiotics or serum as this will effect 
transfection.  
d.  Plasmid Solution: Add 300 µl of opti-MEM to an eppendorf tube and add 150 nM of oligonucleotide. Vortexed tube gently by 
flicking 20 times. 
e.  Lipofectin Solution: Add 4.5 µl of lipofectin to 300 µl of opti-MEM media in a separate tube and gentle vortex by flicking.  
f.  *Note: It is important to keep tubes separate. Some plasmids may interact with plastic in eppendorf tubes be sure to check plasmid 
specifications. 
g.  Combine the two tubes and mix gently, incubate at room temperature for 20-45 minutes to form transfection complex.  
h.  Dilute transfection complex with 2.4 ml of opti-MEM media to each tube. 
i.  *Note: If there is a long transfection and cells do not tolerate serum free media well, the dilution can be done in media with serum. 
However, lipofectin concentration will need to be reoptimized. 
j.  Wash cells with 100 µl of Opti-MEM media to remove serum and add 100 µl of transfection complex to each well. 
k.  Incubate for 4 hours and remove Opti-MEM media. Replace with normal cell media for cells (with serum and antibiotic). 
 
MTT assay of transfected cells 
 
a.  Expose transfected and non-transfected cells to 3 Gy of radiation. 
b.  After the desired time of incubation, add 50 µg of MTT per well. Let plates incubate for 4 h at 37ºC until purple precipitate forms. 
c.  Solubilize the converted purple formazan dye with 100 µl of detergent reagent (0.01 M HCL/10% SDS) per well. Incubated plates 
overnight at 37ºC. 
d.  Quantify reaction product with spectrophotometer set at 570nm absorbance. 